Skip to main content
Erschienen in: AIDS and Behavior 3/2016

08.09.2016 | Original Paper

Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis

verfasst von: J. M. Hugo, R. D. Stall, K. Rebe, J. E. Egan, G. De Swardt, H. Struthers, J. A. McIntyre

Erschienen in: AIDS and Behavior | Sonderheft 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Men who have Sex with Men (MSM) have been affected disproportionately by the global HIV pandemic. Rates of consistent condom-use are low and there is a need for further biomedical prevention interventions to prevent new HIV infections. Post exposure prophylaxis (PEP) can reduce the risk of HIV, but uptake among MSM is low. Pre-exposure prophylaxis (PrEP), an innovative anti-retroviral-based HIV prevention tool might be an appropriate intervention for MSM who have recently accessed PEP that involves HIV negative individuals taking daily tenofovir+emtricitabine for HIV prevention. 44 MSM, attending a primary health-care level MSM-focused sexual health clinic in Cape Town, South Africa, who had initiated PEP were enrolled in this study. Participants were followed up after 2, 4 and 12 weeks. Self-administered electronic surveys were completed at the initial, 4 and 12 week visit. Barriers and facilitators to accessing PEP and remaining adherent were examined, as was knowledge about PrEP. Thirty-two participants (80 %) were <40 years of age (range 20–65 years). 35 % of the participants reported their reason for requiring PEP as condomless receptive anal intercourse. A further 20 % required PEP following condomless penetrative anal intercourse; 27.5 % required PEP due to a broken condom during receptive anal sex and 2 participants during insertive anal sex. Three participants did not complete 28 days of PEP or were lost to follow up. Over half (58.5 %) of the participants reported being completely adherent to their regime; under a third (31.7 %) reported missing one PEP dose; and 9.8 % reported missing more than one dose. 36/40 (90 %) had heard of PrEP and 30/40 (75 %) indicated that they would use PrEP if it were accessible to them. That we enrolled 44 MSM who accessed PEP from a Department of Health affiliated clinic over 12 months, speaks to the low uptake by MSM of PEP services in South Africa. Adherence was high and demonstrates that adherence support is feasible from a state health clinic. Reported risk behaviors in some high-risk participants did not change over time, demonstrating the need for additional longer-term HIV preventions such as PrEP. PEP users could conceivably be transitioned from PEP to PrEP.
Literatur
1.
Zurück zum Zitat Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet. 2009;374(9687):416–22.CrossRefPubMed Smith AD, Tapsoba P, Peshu N, Sanders EJ, Jaffe HW. Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet. 2009;374(9687):416–22.CrossRefPubMed
2.
Zurück zum Zitat Lane T, Raymond F, Dladla S, Rasethe J, Struthers H, McFarland W, et al. High HIV prevalence among men who have sex with men in Soweto, South Africa: results from the Soweto Men’s Study. AIDS Behav. 2009;15(3):626–34.CrossRefPubMedPubMedCentral Lane T, Raymond F, Dladla S, Rasethe J, Struthers H, McFarland W, et al. High HIV prevalence among men who have sex with men in Soweto, South Africa: results from the Soweto Men’s Study. AIDS Behav. 2009;15(3):626–34.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis. 2001;183(5):707–14.CrossRefPubMed Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis. 2001;183(5):707–14.CrossRefPubMed
5.
Zurück zum Zitat Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337(21):1485–90.CrossRefPubMed Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337(21):1485–90.CrossRefPubMed
6.
Zurück zum Zitat Dolezal C, Frasca T, Giguere R, Ibitoye M, Cranston RD, Febo I, et al. Awareness of post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) is low but interest is high among men engaging in condomless anal sex with men in Boston, Pittsburgh, and San Juan. AIDS Educ Prev. 2015;27(4):289–97.CrossRefPubMedPubMedCentral Dolezal C, Frasca T, Giguere R, Ibitoye M, Cranston RD, Febo I, et al. Awareness of post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) is low but interest is high among men engaging in condomless anal sex with men in Boston, Pittsburgh, and San Juan. AIDS Educ Prev. 2015;27(4):289–97.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Sonder GJ, van den Hoek A, Regez RM, Brinkman K, Prins JM, Mulder JW, et al. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000–2004. Sex Transm Dis. 2007;34(5):288–93.PubMed Sonder GJ, van den Hoek A, Regez RM, Brinkman K, Prins JM, Mulder JW, et al. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000–2004. Sex Transm Dis. 2007;34(5):288–93.PubMed
8.
Zurück zum Zitat Grant R, Lama JR, Anderson PL, McMahan V, Liu AY, Goicochea P, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant R, Lama JR, Anderson PL, McMahan V, Liu AY, Goicochea P, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Holzemer WL, Uys L, Makoae L, Stewart A, Phetlhu R, Dlamini PS, et al. A conceptual model of HIV/AIDS stigma from five African countries. J Adv Nurs. 2007;58(6):541–51.CrossRefPubMed Holzemer WL, Uys L, Makoae L, Stewart A, Phetlhu R, Dlamini PS, et al. A conceptual model of HIV/AIDS stigma from five African countries. J Adv Nurs. 2007;58(6):541–51.CrossRefPubMed
12.
Zurück zum Zitat Koblin BA, Team ES. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. The Lancet. 2004;364(9428):41–50.CrossRef Koblin BA, Team ES. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. The Lancet. 2004;364(9428):41–50.CrossRef
13.
Zurück zum Zitat University of California SF. Report of the South Africa men-who-have-sex-with-men Data Triangulation Project. San Fransisco: UCSF. Global Health Sciences; 2015. University of California SF. Report of the South Africa men-who-have-sex-with-men Data Triangulation Project. San Fransisco: UCSF. Global Health Sciences; 2015.
14.
Zurück zum Zitat Krakower DS, Jain S, Mayer KH. Antiretrovirals for primary HIV prevention: the current status of pre-and post-exposure prophylaxis. Current HIV/AIDS Rep. 2015;12(1):127–38.CrossRef Krakower DS, Jain S, Mayer KH. Antiretrovirals for primary HIV prevention: the current status of pre-and post-exposure prophylaxis. Current HIV/AIDS Rep. 2015;12(1):127–38.CrossRef
15.
Zurück zum Zitat Jain S, Krakower DS, Mayer KH. The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention. Clin Infect Dis. 2015;60(suppl 3):S200–4.CrossRefPubMedPubMedCentral Jain S, Krakower DS, Mayer KH. The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention. Clin Infect Dis. 2015;60(suppl 3):S200–4.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Pitasi MA, Bingham TA, Sey EK, Smith AJ, Teshale EH. Hepatitis B virus (HBV) infection, immunity and susceptibility among men who have sex with men (MSM), Los Angeles County. USA. AIDS Behav. 2014;18(Suppl 3):248–55.CrossRefPubMed Pitasi MA, Bingham TA, Sey EK, Smith AJ, Teshale EH. Hepatitis B virus (HBV) infection, immunity and susceptibility among men who have sex with men (MSM), Los Angeles County. USA. AIDS Behav. 2014;18(Suppl 3):248–55.CrossRefPubMed
18.
Zurück zum Zitat Fairley CK, Read TR. Vaccination against sexually transmitted infections. Curr Opin Infect Dis. 2012;25(1):66–72.CrossRefPubMed Fairley CK, Read TR. Vaccination against sexually transmitted infections. Curr Opin Infect Dis. 2012;25(1):66–72.CrossRefPubMed
Metadaten
Titel
Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis
verfasst von
J. M. Hugo
R. D. Stall
K. Rebe
J. E. Egan
G. De Swardt
H. Struthers
J. A. McIntyre
Publikationsdatum
08.09.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe Sonderheft 3/2016
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1536-1

Weitere Artikel der Sonderheft 3/2016

AIDS and Behavior 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.